Final day of buying and selling on Nasdaq Copenhagen will probably be 11 December 2020 and the primary day of buying and selling on Nasdaq First North Progress Market Denmark will probably be 14 December 2020
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Firm”), a clinical-stage biotechnology firm specializing within the growth of progressive medication focusing on tumor DNA Injury response (DDR), specifically towards uncommon or resistant cancers, has acquired approval for the delisting from Nasdaq Most important Market Copenhagen and the concurrent admission to buying and selling on Nasdaq First North Progress Market Denmark.
As described in firm announcement on 27 November 2020, Onxeo has utilized for admission to buying and selling on Nasdaq First North Progress Market Denmark and the concurrent delisting from Nasdaq Most important Market Copenhagen.
Nasdaq Copenhagen has at the moment notified the Firm of their approval of the functions.
Consequently the final buying and selling day on Nasdaq Most important Market Copenhagen will probably be 11 December 2020 and the primary day of buying and selling on Nasdaq First North Progress Market Denmark will probably be 14 December 2020.
The Firm will now not be topic to the disclosure necessities within the Capital Markets Act (“Kapitalmarkedsloven”) and shareholders will now not be required to tell about their shareholdings in response to the Capital Markets Act. As a substitute the Firm will probably be topic to the principles of the Nasdaq First North Progress Market Rulebook that doesn’t have the identical firm disclosure necessities because the Capital Markets Act and doesn’t require shareholders to report their shareholdings within the Firm.
The Firm will proceed to be topic to the principles and necessities of the Market Abuse Regulation.
Goal of switch
The aim of each transfers is to permit Onxeo to be listed on a market which is extra appropriate to the Firm’s measurement and its market capitalization. The transfers to Euronext Progress Paris and First North Progress Market ought to present the Firm with a regulatory framework that’s higher suited to a SME and cut back listing-related prices, whereas nonetheless benefiting from entry to the monetary markets.
Penalties for Onxeo shareholders
Nasdaq Most important Market has the authorized standing of a regulated market, whereas Nasdaq First North Progress Market is legally thought of a SME Progress Market, which is a Multilateral Buying and selling Facility. Upon switch from the Most important Market to First North Progress Market, guidelines for Danish shareholders usually are not modified or completely different as regards taxes and pensions and there’s no consequence on the tax therapy of capital positive aspects and losses.
Non-Danish shareholders may be coated by different tax and pension guidelines, relying totally on the tax residence of the shareholder and, amongst different issues, on how and when the shareholder has invested within the firm. These shareholders are due to this fact inspired to hunt impartial recommendation in relation to the tax penalties from their very own auditor and recommendation on pension deposits from their very own bank.
Nasdaq First North Progress Market Disclaimer
Nasdaq First North Progress Market is a registered SME development market, in accordance with the Directive on Markets in Monetary Devices (EU 2014/65) as applied within the nationwide laws of Denmark, Finland and Sweden, operated by an exchange throughout the Nasdaq group. Issuers on Nasdaq First North Progress Market usually are not topic to all the identical guidelines as issuers on a regulated essential market, as outlined in EU laws (as applied in nationwide regulation). As a substitute they’re topic to a much less intensive algorithm and rules adjusted to small development firms. The danger in investing in an issuer on Nasdaq First North Progress Market may due to this fact be increased than investing in an issuer on the principle market. All issuers with shares admitted to buying and selling on Nasdaq First North Progress Market have a Licensed Adviser who displays that the principles are adopted. The respective Nasdaq exchange approves the applying for admission to buying and selling.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology firm creating progressive oncology medication focusing on tumor DNA-binding capabilities by distinctive mechanisms of motion within the sought-after subject of DNA Injury Response (DDR). The Firm is concentrated on bringing early-stage first-in-class or disruptive compounds from translational analysis to scientific proof-of-concept, a value-creating inflection level interesting to potential companions.
platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides appearing as decoy agonists, which generates new progressive compounds and broaden the Firm’s product pipeline.
AsiDNA™, the primary compound from platON™, is a first-in-class, extremely differentiated DNA Injury Response (DDR) inhibitor based mostly on a decoy and agonist mechanism appearing upstream of a number of DDR pathways. Translational analysis has highlighted the distinctive properties of AsiDNA™, notably its means to abrogate tumor resistance to PARP inhibitors whatever the genetic mutation standing. AsiDNA™ has additionally proven a robust synergy with different tumor DNA-damaging brokers similar to chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Restore Inhibitor-administered IntraVenously) part I research has evaluated AsiDNA™ by systemic administration (IV) in superior stable tumors and confirmed the lively doses in addition to a good human security profile. The continuing DRIIV-1b extension research is assessing the security and efficacy of a 600 mg dose of AsiDNA™ together with carboplatin after which with carboplatin and paclitaxel, in sufferers with stable tumors who’re eligible for such remedies. Preliminary outcomes from the primary cohort with carboplatin alone confirmed good tolerability, stabilization of the illness and a rise within the length of therapy in comparison with earlier remedies.
OX401 is a brand new drug candidate from platON™, optimized to be a next-generation PARP inhibitor appearing on each the DNA Injury Response and the activation of immune response, with out inducing resistance. OX401 is present process preclinical proof-of-concept research, alone and together with immunotherapies.
For additional data, please go to www.onxeo.com.
Ahead wanting statements
This communication expressly or implicitly accommodates sure forward-looking statements regarding Onxeo and its enterprise. Such statements contain sure identified and unknown dangers, uncertainties and different elements, which may trigger the precise outcomes, monetary situation, efficiency or achievements of Onxeo to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by such forward-looking statements. Onxeo is offering this communication as of this date and doesn’t undertake to replace any forward-looking statements contained herein on account of new data, future occasions or in any other case. For a dialogue of dangers and uncertainties which may trigger precise outcomes, monetary situation, efficiency or achievements of Onxeo to vary from these contained within the forward-looking statements, please seek advice from chapter 3 “Danger Components” (“Facteurs de Risque“) of the Firm’s common registration doc filed with the Autorité des marchés financiers on April 27, 2020 underneath quantity D.20-0362, which is obtainable on the web sites of the Autorité des marchés financiers (www.amf-france.org) an the Firm (www.onxeo.com).
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20201130005413/en/
+33 1 45 58 76 00
+33 1 44 71 94 98
Investor Relations / Strategic Communication
Dušan Orešanský / Emmanuel Huynh
+33 1 44 71 94 92
Investor Relations US
+1 212 915 2578
+45 89 88 78 46